Cortical Visual Mapping following Ocular Gene Augmentation Therapy for Achromatopsia

J Neurosci. 2021 Sep 1;41(35):7363-7371. doi: 10.1523/JNEUROSCI.3222-20.2021. Epub 2021 Aug 4.

Abstract

The ability of the adult human brain to develop function following correction of congenital deafferentation is controversial. Specifically, cases of recovery from congenital visual deficits are rare. CNGA3-achromatopsia is a congenital hereditary disease caused by cone-photoreceptor dysfunction, leading to impaired acuity, photoaversion, and complete color blindness. Essentially, these patients have rod-driven vision only, seeing the world in blurry shades of gray. We use the uniqueness of this rare disease, in which the cone-photoreceptors and afferent fibers are preserved but do not function, as a model to study cortical visual plasticity. We had the opportunity to study two CNGA3-achromatopsia adults (one female) before and after ocular gene augmentation therapy. Alongside behavioral visual tests, we used novel fMRI-based measurements to assess participants' early visual population receptive-field sizes and color regions. Behaviorally, minor improvements were observed, including reduction in photoaversion, marginal improvement in acuity, and a new ability to detect red color. No improvement was observed in color arrangement tests. Cortically, pretreatment, patients' population-receptive field sizes of early visual areas were untypically large, but were decreased following treatment specifically in the treated eye. We suggest that this demonstrates cortical ability to encode new input, even at adulthood. On the other hand, no activation of color-specific cortical regions was demonstrated in these patients either before or up to 1 year post-treatment. The source of this deficiency might be attributed either to insufficient recovery of cone function at the retinal level or to challenges that the adult cortex faces when computing new cone-derived input to achieve color perception.SIGNIFICANCE STATEMENT The possibility that the adult human brain may regain or develop function following correction of congenital deafferentation has fired the imagination of scientists over the years. In the visual domain, cases of recovery from congenital deficits are rare. Gene therapy visual restoration for congenital CNGA3-achromatopsia, a disease caused by cone photoreceptor dysfunction, gave us the opportunity to examine cortical function, to the best of our knowledge for the first time, both before and after restorative treatment. While behaviorally only minor improvements were observed post-treatment, fMRI analysis, including size algorithms of population-receptive fields, revealed cortical changes, specifically receptive field size decrease in the treated eyes. This suggests that, at least to some degree, the adult cortex is able to encode new input.

Keywords: achromatopsia; color; plasticity; population-receptive field; vision; visual cortex.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Brain Mapping / methods*
  • Color Perception
  • Color Vision Defects / congenital
  • Color Vision Defects / genetics
  • Color Vision Defects / physiopathology*
  • Color Vision Defects / therapy
  • Cyclic Nucleotide-Gated Cation Channels / deficiency
  • Electroretinography
  • Female
  • Fixation, Ocular
  • Gene Duplication
  • Genetic Therapy / methods*
  • Genetic Vectors / administration & dosage
  • Genetic Vectors / therapeutic use
  • Humans
  • Injections, Intraocular
  • Magnetic Resonance Imaging*
  • Male
  • Mutation, Missense
  • Photophobia / etiology
  • Photophobia / therapy
  • Retinal Cone Photoreceptor Cells / physiology
  • Treatment Outcome
  • Visual Acuity
  • Visual Cortex / physiopathology*

Substances

  • CNGA3 protein, human
  • Cyclic Nucleotide-Gated Cation Channels